Olmetec Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmetec Plus, is an angiotensin II receptor blocker presented as a tablet for oral use. It is employed in the management of hypertension in adult patients. GNH USA supplies Olmetec Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmetec Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmetec Plus combines two agents that act on the renin‑angiotensin‑aldosterone system to lower blood pressure.

- Hypertension: helps achieve target blood pressure levels in adults. - Heart failure with reduced ejection fraction: used as part of combination therapy to improve clinical outcomes. - Diabetic nephropathy: provides renal protection by reducing intraglomerular pressure.

Olmetec Plus may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Liver function abnormalities - Blood‑cell abnormalities such as neutropenia

Olmetec Plus should be used with caution in several clinical situations.

- Renal impairment: dose may need adjustment and renal function monitoring. - Hepatic impairment: monitor liver enzymes regularly. - Electrolyte imbalance: check serum potassium and sodium levels. - Pregnancy: contraindicated in the second and third trimesters. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmetec Plus can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren: combined use may increase risk of renal dysfunction and hyperkalemia. - Potassium‑rich supplements or salts: may cause dangerous hyper‑kalaemia. - Lithium: increased lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs: additive risk of hyper‑kalaemia and renal impairment. - Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.